Skip to content

You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.

Request a United Therapeutics sales representative

If you would like to speak with a United Therapeutics Cardiopulmonary Sales Specialist, please fill out the form and click SUBMIT, and someone will contact you shortly.

*Required field.

Please input a valid First Name

Please input a valid First Name

Please input a valid Last Name

Please input a valid Last Name

Please input a valid e-mail address

Please input a valid e-mail address

Please input a valid ZIP code

Please input a valid ZIP code

Please input a valid Phone Number

Please input a valid Phone Number

Please input a valid NPI Number
Please input a valid NPI Number
NPI Search

If you do not know your NPI number, please use the simple search function below. Enter your name and ZIP Code, then click SEARCH, then click on your NPI number to add it to the form. When your form fields have been filled, click SUBMIT to complete the response.

Please input a valid First Name

Please input a valid First Name

Please input a valid Last Name

Please input a valid Last Name

Please input a valid ZIP Code

Please input a valid ZIP Code

NPINameAddress

Privacy

United Therapeutics respects your right to have your personal information kept private. We may use this information to send you materials on our products and services that may be of interest to you. We will not share your information with any third parties or outside mailing lists.

Clicking the SUBMIT button signifies that you have read and agree to our Privacy Policy, and that you agree to receive future communications from orenitram.com or United Therapeutics Corporation. You can unsubscribe at any time.

Important Safety Information

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

Indication

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).

NPI=National Provider Identifier.